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Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant inherited tumor
syndrome, associated with parathyroid, pituitary, and gastro-entero-pancreatic (GEP)
neuroendocrine tumors (NETs). MEN1 is usually consequent to different germline and
somatic mutations of the MEN1 tumor suppressor gene, although phenocopies have also
been reported. This review analyzed main biomedical databases searching for reports on
MEN1 gene mutations and focused on aggressive and aberrant clinical manifestations to
investigate the potential genotype-phenotype correlation. Despite efforts made by several
groups, this link remains elusive to date and evidence that aggressive or aberrant clinical
phenotypes may be related to specific mutations has been provided by case reports and
small groups of MEN1 patients or families. In such context, a higher risk of aggressive tumor
phenotypes has been described in relation to frameshift and non-sense mutations, and
predominantly associated with aggressive GEP NETs, particularly pancreatic NETs. In our
experience a novel heterozygous missense mutation at c.836C>A in exon 6 was noticed in a
MEN1 patient operated for macro-prolactinoma, who progressively developed recurrent
parathyroid adenomas, expanding gastrinomas and, long after the first MEN1manifestation, a
neuroendocrine uterine carcinoma. In conclusion, proof of genotype-phenotype correlation is
limited but current evidence hints at the need for long-term interdisciplinary surveillance in
patients with aggressive phenotypes and genetically confirmed MEN1.
Keywords: MEN1, genotype, phenotype, mutations, tumorsINTRODUCTION
Multiple endocrine neoplasia type 1 (MEN1) syndrome (OMIM#131100) is a rare autosomal
dominant inherited tumor syndrome with high penetrance, that is typically associated with
parathyroid, pituitary, and gastro-entero-pancreatic (GEP) neuroendocrine tumors (NETs),
either functioning or nonfunctioning (1, 2). Adding to the intrinsic burden of MEN1, a differentn.org November 2020 | Volume 11 | Article 5915011
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develop, i.e. carcinoids (thymic, bronchial), adrenocortical
tumors, facial angiofibromas, lipomas, and collagenomas (3–5).
The clinical behavior of MEN1 largely depends on tumor
spread and histological features, as well as type and degree of
hormone hypersecretion, risk of tumor recurrence, and duration
of surveillance (6). The MEN1 gene (NM_130799.2) is a tumor-
suppressor gene located on chromosome 11q13 (7, 8). This gene
spans approximatively 9,000 bp of genomic DNA containing 10
exons and is transcribed into a 2.8 kb mRNA with the
translational start codon (ATG) in exon-2 and the stop-codon
in exon-10. The protein product of the MEN1 gene is called
MENIN, of which different isoforms have been reported: long
isoform 1, 615 amino acids, chosen as the canonical sequence,
short isoform 2, 610 amino acids length, and isoform 3 consisting
of 575 amino acids (9). MENIN nuclear localization sequences
(NLSs) are located in its C-terminal region and directly interact
with DNA in a sequence-independent manner to serve as a
scaffold protein that controls gene expression and cell signaling
(10). The majority of patients with the inherited form of the
disease carry germline mutations of the MEN1 gene (11).
Germline heterozygous inactivating mutations were found in
the coding region of the MEN1 gene in index cases and affected
family members, together with loss of heterozygosity (LOH) for
markers at theMEN1 gene locus in their tumors as expected for a
causative tumor suppressor gene (12–14). To date, many
germline or somatic mutations have been described both in
MEN1 families and sporadic cases (15–18).
MEN1 gene mutations are distributed throughout the coding
region without particular hot spot regions. Since the original
description of the MEN1 gene, different germline MEN1
mutations have been identified across its coding sequences (6,
15). Approximatively 10% of the MEN1 mutations arise de novo
and are later transmitted to following generations (19). More
than 10% of mutations are nonsense mutations, 40% frameshift
insertions and deletions, 25% missense mutations while 11% are
splice site defects (20). Generally, the MEN1-related tumors
occurrence requires inheritance of a germline mutation of
MEN1 gene together with a somatic mutation in the DNA of
tumor, leading to LOH, according to the two hits model by
Knudsons’ (13, 15). However, in multifocal MEN1-gastrinomas,
with Zollinger–Ellison syndrome, it has been described that LOH
at 11q13 region can be found in less than 50% of patients, and
within the same patient different tumoral foci frequently
exhibited different patterns of LOH, ranging from LOH limited
only to 11q13 to loss of the whole chromosome or no LOH,
suggesting that each focus of gastrinoma may arise by an
independent second hit (21). It has been also hypothesized that
preneoplastic G-cells hyperplastic lesions, and similarly to what
described in somatostatin‐secreting tumors from the same
patients, may retain both MEN1 alleles and that LOH and/or
MEN1 gene mutation, reported to be present in 54% of tumors
lacking evidence of LOH, may account for the initiation step of
neoplastic lesions (21). Lack of mutations have been reported in
5–25% of patients with a clinical diagnosis of MEN1, constituting
the so-called “phenocopies” (15, 22, 23). Of note, a recent studyFrontiers in Endocrinology | www.frontiersin.org 2on 189 patients with typical MEN1 phenotype described a higher
prevalence (74%) of mutation-negative cases than previously
reported (24).
Interest has increasingly focused on the genetic mutations
associated with MEN1 hinting at potential genotype-phenotype
correlations. To date, genotype-phenotype correlations in MEN1
have been difficult to assess, and the nature of mutations appears
to play a null role in clinical MEN1 features, i.e. age of onset,
multicentricity, recurrence or markers of aggressiveness (25, 26).
Opposed to MEN1 syndrome, the existence of a strong genotype-
phenotype correlation has been demonstrated in genetic studies
of MEN2 syndrome (1). In the present narrative review, we sought
to summarize evidences from the literature on peculiarMEN1 gene
mutations with a focus on aggressive and/or aberrant clinical
presentations. The search for relevant original publications and
case reportswritten in Englishwas performedonPubMed, Embase,
Scopus, and Google Scholar using the NCI Dictionary of Cancer
Terms: multiple endocrine neoplasia type 1 OR MEN1 AND
phenotype OR genotype, multiple endocrine neoplasia type 1 OR
MEN1 AND genotype-phenotype correlation, multiple endocrine
neoplasia type 1 OR MEN1 AND aggressive, multiple endocrine
neoplasia type 1 OR MEN1 AND aberrant. As an index case, we
describe a MEN1 patient harboring a novel sporadic germline
mutation and late aggressive clinical features, so as to further
discuss the potential clues underlying a genotype–phenotype
correlation in MEN1.GENE MUTATIONS INVOLVED IN THE
PATHOGENESIS OF MEN1
Since the MEN1 gene has been identified, 1,698 mutations have
been described (17). Of these, approximately 85% are germline
and 15% are somatic mutations (15, 27). Germline MEN1
mutations consist of about 460 different mutations, distributed
throughout the 1,830 bp coding region and splice sites of the
MEN1 gene (27).
Different types ofMEN1 gene mutations and their frequencies
have been summarized in Table 1. These mutations are dispersed
throughout the coding region of the gene rather than beingTABLE 1 | Different types of gene mutations associated with MEN1 and their
frequencies.
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inactivating, as it often happens for tumor suppressor genes
(17). A few mutations repeatedly described in unrelated families,
refer to 9 sites in theMEN1 gene, and account for over 20% of all
germline mutations (27). These mutations are recurrent and
possibly represent hot spots. Deletion or insertion of these hot
spots elements has also been reported in association with DNA
sequence repeats, DNA stretches of long strips of either single
nucleotides or shorter repeat elements (28).
Approximatively 5–10% of MEN1 patients may show no
evident germline mutations in the MEN1 gene coding region
(12, 14, 28–31) but they may harbor large mutations or deletions
in the promoter or untranslated regions, which have not been
described to date (27). Large deletions are hard to detect by
conventional Sanger sequencing, and multiplex ligation-
dependent probe amplification (MLPA) (32) or next-generation
sequencing (NGS) technology, specifically whole genome testing, or
long-read sequencing, the latter enabling also detection of intronic
or promoter mutations, are predicted tomore accurately extrapolate
information on such large gene rearrangements (33).
Additional genetic mechanisms have been recently investigated
for their possible involvement inMEN1 phenotype (27). Particular
interest has focused on the p27Kip1 protein, which is encoded by
the CDKN1B gene and is located downstream of MEN1-driven
tumorigenesis (34). The V109G variant of p27 has been reported to
influence the clinical manifestation of MEN1 subjects who carry
truncating MEN1 gene mutations (34). Carriers of both genetic
variants, i.e. truncatingMEN1mutation andV109G variant, show a
more aggressive clinical behavior with a worse prognosis of the
syndrome (35). These mechanisms will subsequently be detailed.THE CLASSICAL CLINICAL SPECTRUM
OF MEN1
Clinical manifestations of MEN1 are predominantly associated
with classical endocrine tumors and their relative secretion
products (28). Typically, MEN1 is characterized by the
presence of several endocrine tumors in the parathyroids, the
pituitary gland and the GEP tract. Possible concomitant
bronchial, thymic, type II gastric entero-chromaffin-Like (ECL)
NETs, and adrenocortical tumors have also been reported.
Likewise, a variable number of other endocrine and non-
endocrine tumors have been described in the context of MEN1
phenotype, such as central nervous system (CNS) and cutaneous
tumors, and will be subsequently summarized (36). MEN1 can
affect all age groups, from 5 to 82 years (37, 38), although clinical
and/or biochemical manifestations onset in nearly 95% of
patients by the fifth decade (39). MEN1 affects both genders
equally, and a recent series of 734 cases described a 57.8% female
predominance (40).
Parathyroid Tumors
Parathyroid tumors, resulting in primary hyperparathyroidism
(PHPT), affect up to 95% of MEN1 patients and represent the
first manifestation of the syndrome, with more than 85% of casesFrontiers in Endocrinology | www.frontiersin.org 3between ages 20 and 25 years (1, 39, 41, 42). PHPT manifests
with hypercalcemia in 100% of affected patients by age 50 years
(43). Compared to sporadic PHPT, bone disease and urolithiasis
in MEN1-related PHPT reportedly show an early onset and
higher severity (44–46). Interestingly, Kanazawa and colleagues
demonstrated, in isolated Men1 knock-out osteoblasts model,
that menin may play a key role in bone development,
remodeling, and maintenance of bone mass in vivo (47),
although in patients with germline MEN1 mutations a specific
genotype-phenotype correlation has never been described in
this regard.
GEP-NETs Tumors
GEP tumors occur in 70–80% of patients and mainly consist of
gastrinomas (the most frequent functioning pancreatic tumor),
glucagonomas, insulinomas, vaso-active intestinal peptidomas
(VIPomas), and non-functioning tumors (28, 39, 42).
More than 80% of MEN1-associated gastrinomas exhibit, at
pathology, multiple microgastrinomas within the first and second
duodenum portion (48). Gastrinomas are usually associated with
hypergastrinemia, increased gastric acid secretion andpeptic ulcers,
a clinical combination usually referred to as the Zollinger-Ellison
syndrome (ZES) (22). Approximatively 50% of MEN1-associated
duodenal microgastrinomas harbor LOH at the MEN1 locus (49).
MEN1-associated gastrinomas exhibit a malignant course and
metastasize to local lymph nodes and liver in about 50% of cases,
even before diagnosis (48, 50). Liver metastases negatively affect
prognosis and survival, whereas lymph node metastases do not
seem to affect the prognosis (51).
Interestingly, considering that most patients with ZES are
treated for long periods with proton pump inhibitors (PPI), a
debate has recently emerged on the potential sensitivity to PPI-
related secondary hypergastrinemia, leading to a potential
increased risk of gastric neuroendocrine tumors, as well as
other tumors (52).
In the context of MEN1, insulinomas are the second most
prevalent functioning pancreatic tumor. They are characterized
by hypoglycemia and the typical Whipple’s triad, which is the
first clinical manifestation of MEN1 syndrome in about 10% of
subjects (36, 53). MEN1 insulinomas usually manifest as single
benign lesions (54), often sized >1 cm, in the setting of multiple
islet macroadenomas (55).
Glucagonomas and VIPomas are infrequent and often
present as large lesions (>3 cm) with predominant benign
behavior. Glucagonomas occur in fewer than 3% of subjects
with MEN1 (56). Symptoms are often vague and the typical signs
of skin rash, anemia, weight loss, and stomatitis can be absent,
while mass effects can be present (22). In asymptomatic MEN1
patients, the presence of the tumor can be suspected upon
pancreatic imaging in the presence of glucose intolerance and
hyperglucagonemia (22). VIPomas are clinically characterized by
watery diarrhea with achlorhydria and hypokalemia (57).
Non-functioning GEP NETs are the most frequent tumor
types. They occur in approximately 55% of MEN1 subjects and
are often multiple, asymptomatic or cause compressive
symptoms (58). An accurate identification of non-functioningNovember 2020 | Volume 11 | Article 591501
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tumors could have a malignant course, which represent the most
frequent cause of death in MEN1 patients; 2) several studies
demonstrated that non-functioning GEP NETs are associated
with a worse prognosis compared to other functioning tumors;
3) the absence of a clinical syndrome and specific biomarkers can
result in delayed diagnosis, which increase the mortality rate
(22, 59).
Anterior Pituitary Tumors
Anterior pituitary tumors occur in about 30% of subjects and
represent the first phenotypic manifestation of MEN1 in up to
42%of sporadic cases (28, 41, 42, 60). In 65–85%ofMEN1patients,
pituitary tumors are represented by macroadenomas, a proportion
that exceeds that recorded in sporadic tumors (55, 60). Inabout30%
of cases, pituitary tumors are locally invasive (60). Prolactinomas
are the most prevalent pituitary adenomas in the context of MEN1
(65%), followed by somatotropinomas, ACTH-secreting tumors,
and non-functioning tumors, the frequency of which is often
overlooked (61). Clinical manifestations of pituitary adenomas in
patients with MEN1 parallel those of sporadic tumors, hence they
depend on hormone hypersecretion, tumor size, pathological
features, and pituitary reserve. Depending on specific pituitary
hormone hypersecretion, patients could manifest symptoms of
hyperprolactinemia (e.g. galactorrhea, amenorrhea, and infertility
inwomen, impotenceand infertility inmen)ordevelop somatic and
metabolic alterations associated with Cushing’s disease or
acromegaly. Large and/or invasive pituitary tumors could
compress adjacent structures including the normal pituitary
tissue and the optic chiasm, leading to hypopituitarism and/or
visual disturbance (22).
Other Endocrine Tumor Types
Adrenal cortical tumors are not rare in patients with MEN1,
occurring in approximately one-fourth of patients with
genetically confirmed MEN1 (5). Less than 10% of subjects
with adrenal tumors show hormonal hypersecretion (62–64),
mainly consisting of primary hyperaldosteronism and/or
hypercortisolism (65). In 2002, Langer et al. conducted a
clinical study with the aim of monitoring 66 patients with
confirmed MEN1 germline mutations in a screening program
that included evaluation of the adrenal glands. They observed
that patients with mutations in exons 2 and 10 of theMEN1 gene
develop adrenal lesions more often than subjects with other
mutations of the MEN1 gene. The malignant potential of MEN-
1-related adrenal neoplasia is of clinical relevance (5).
Approximately 10% of MEN1 patients can develop thymic,
bronchial, or type II gastric ECL carcinoids. Thymic NETs are
aggressive malignant tumors that preferentially occur in male
smokers (66). Their detection is largely dependent on imaging
studies. In women, carcinoids are primarily multicentric and
metasynchronous bronchial NETs and their course is generally
indolent (66, 67). However, Lecomte et al. described cases of
poorly differentiated and aggressive bronchial NETs, which are
associated with an increased mortality (68).Frontiers in Endocrinology | www.frontiersin.org 4Non-endocrine Tumors
MEN1 patients can also develop lipomas, collagenomas, facial
angiofibromas, CNS tumors including meningiomas and
ependymomas, and smooth-muscle tumors, including
leiomyomas (1, 4, 30, 39, 41, 51).
Skin tumors tend to be multiple and their diagnosis often
precedes the onset of clinical hormone-dependent manifestations,
thus contributing to early diagnosis of MEN1 (69, 70).
Subcutaneous, pleural, visceral, or retroperitoneal lipomas (34%),
facial angiofibromas (88%), and collagenomas (72%) may occur
frequently in patients with MEN1 (1, 71). CNS tumors include
asymptomatic meningiomas in 8% of MEN1 patients (70), while
ependymomas and schwannomas affect about 1% of cases (72).
Recently, the case of aMEN1-relatedmature teratoma and yolk sac
testis tumor has been described (73).AGGRESSIVE AND ABERRANT
PHENOTYPE OF MEN1
Cases of MEN1 phenotypes featured by aggressive or aberrant
presentation, malignant evolution, and unfavorable clinical
course have been reported in the literature and will be
followingly summarized.
Parathyroid Carcinoma
The presence of parathyroid carcinoma in association with MEN1
has been so far described in 16 cases (74–84). The clinical
characteristics of these cases are reported in Table 2. In 2016, a
single tertiary care center study conducted from 1997 to 2013 in a
cohort of 348 patients with MEN1 syndrome, reported only one
case of parathyroid carcinoma with a prevalence of 0.28% (80). In
the same year, Christakis et al. collected 291 cases with a genetic
and/or clinical diagnosis ofMEN1 fromtheMDAndersonpatients’
database (81). Hyperparathyroidism was diagnosed in 242 of these
patients (83.2%) with two of them receiving a histopathologic
diagnosis of parathyroid carcinoma which accounted for an
overall prevalence of 0.8%, while 1 patient (0.4%) received a
diagnosis of atypical parathyroid neoplasm. Then, progression to
malignancy does not seem tobe a prerogative ofMEN1parathyroid
tumors. Interestingly, MEN1 gene an inactivating mutation and a
splicing mutation, previously identified in subjects who developed
malignant lesions, has been reported, thus suggesting a possible
genotype−phenotype association (89, 90).
Malignant Insulinoma and Glucagonoma
Malignant insulinomas are rare, hence scant data exist on their
prevalence and clinical presentation in MEN1 patients. In 2011,
Hasani-Ranjbar et al. described a large family encompassing
several members from three generations who were evaluated for
MEN1. Genetic analysis was performed in all family members
using PCR amplification of coding regions followed by direct
sequencing. In three brothers presenting with hypoglycemia, the
presence of insulinomas was confirmed and in two cases it was
malignant, according to the surgery and pathology report. Two
of these presented with hyperparathyroidism as well. MutationNovember 2020 | Volume 11 | Article 591501
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screening revealed the presence of a two nucleotides deletion in
the exon 2 resulting in a non-functional gene product (91).
Recently, Novruzov et al. reported another case of malignant
insulinoma with multiple metastatic lesions in the right lung,
liver, and pancreas, in a 54-year-old man, who had a previous
history parathyroid surgery and left thyroid lobectomy (92).
Only one case of malignant glucagonoma with cervical
metastases has been reported to date in MEN1 (88).
Pituitary Carcinoma
Only four cases of pituitary carcinoma have been described in
association with MEN1 (79–82). In 2005, Benito and co-workers
described the first case of a woman with a MEN1 associated
gonadotroph carcinoma, who developed a temporal lobe
metastasis (93). One year later, Gordon et al. presented the
case of a 47-year-old male patient with MEN1 who was affected
by parathyroid adenomas, non-functioning pancreatic tumors
and a metastatic prolactinoma presenting as a cervical spinal
cord lesion (94). Another case of malignant prolactinoma was
described by Philippon and co-workers (95). Finally, Scheithauer
et al. described the case of a 19-year-old man with a peculiar
MEN1 phenotype, characterized by a parathyroid adenoma,
pancreatic islet cell tumors in association with two enlarged
hepatic hilar lymph nodes that were not biopsied, and a non-
functioning pituitary mass with supra- and parasellar invasion,
harboring craniospinal and systemic metastases (96).
Adrenocortical Carcinoma
The incidence of adrenocortical carcinoma in patients with
MEN1 has been reported as ranging between 1.4 and 6% (65,
97). The prevalence of adrenocortical carcinoma is reportedly 10
times higher in patients with adrenal tumors and MEN1 as
compared to those with adrenal incidentalomas without MEN1
(64). Adrenocortical carcinoma can exhibit familial aggregation
in MEN1 patients. In reviewing literature, we could document 22
cases of adrenocortical carcinoma associated with MEN1 (5, 63,
65, 97–105). The most peculiar and aggressive MEN1
phenotypes associated with adrenocortical carcinoma were
recently described (104, 105). Wang et al. described the case of
a 51-year-old man with MEN1-associated bilateral parathyroid
adenoma, multiple pNETs, and left adrenocortical carcinoma,
which metastasized to supraclavicular and mediastinal lymph
nodes, bilateral lung, and uncinate process of pancreas (104). In
the same year, Harada et al. reported the case of a 68-year-old
woman with a complex MEN1 phenotype characterized by
pancreatic insulinoma, breast cancer, non-functioning pituitary
tumor, parathyroid adenoma, and a myxoid variant of
adrenocortical carcinoma without metastases (105).
Other Neoplasms
Ovarian NETs are rare and comprise 0.1% of all ovarian tumors.
To date, few cases of primary ovarian NETs in women with
MEN1 syndrome have been described in association with clinical
manifestations of MEN1, but without genetic testing (106–109).
More recently, clinical cases of ovarian NETs have been reported
in genetically tested MEN1 cases. Jhawar et al. reported on a
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ovarian carcinoid has been described as the first manifestation of
an otherwise occult MEN1 syndrome in a 30-year old woman,
who later developed a contralateral lesion two years after initial
diagnosis (108). In this case, subsequent work-up allowed
identification of simultaneous multifocal endocrine tumors
involving parathyroids, thymus, adrenal glands, and pancreas,
along with metastatic lesions in lymph nodes, liver, and bones.
Non-endocrine Malignancies
Recent studies suggest a general role of menin in carcinogenesis
that may affect the risk and clinical course of developing
common non-endocrine neoplasms (22). The most frequent
non-endocrine neoplasm in MEN1 is breast cancer, which is in
the MEN1 setting characterized by earlier onset as compared to
non-MEN1 patients (110). The calculated relative risk for breast
cancer in MEN1 women is 2.83 (111), which advises to
categorize the MEN1 gene as a moderate risk factor for breast
cancer (112). Interestingly, it has been also described a patient
harboring bothMEN1 and BRCA1 germline mutations in whom
the severity of the MEN1-related biochemical and clinical
findings did not differ from those for other affected family
members lacking the BRCA1 mutation, but she did not
develop any BRCA1-related malignancies (113). Other cancers
that have been anecdotally described in association with MEN1
include hepatocellular carcinoma (114), melanoma (115–118),
lung adenocarcinoma (103), renal cell carcinoma (119, 120),
papillary thyroid cancer (120–122), and prostate cancer
(120, 123).THE NATURAL HISTORY OF MEN1
PATIENTS
MEN1 patients have an increased risk of premature death. Earlier
studies reported an average life-span of 50 years in affected patients
(124, 125). The leading cause of death is complications related to
hypergastrinemia and hyperparathyroidism. Although the
improvement of medical and surgical management has
remarkably decreased the risk of premature deaths for such
causes, survival curves in MEN1 patients remain significantly
affected when compared to the general population (126). Main
negative prognostic factors in MEN1 patients include clinical
features, i.e. disease duration, presence of non-ZES functional
syndromes, number of parathyroidectomies, occurrence of thymic
carcinoid, family history and, in case of ZES, a previous acid-
reducing surgery. Also, entity of hypergastrinemia and tumor
features, such as pNETs size, liver metastases, distant metastases,
number of lesions at imaging, and tumor growth, are also reported
to play a role (126).
To date, there are only few prospective studies evaluating the
long-term course and causes of death of MEN1 patients. In 2013,
Ito et al. conducted a prospective study with the aim of
describing the current course of MEN1 patients late in the
disease history and the causes of death at present (126).
Opposed to previous reports, this and other large MEN1 seriesFrontiers in Endocrinology | www.frontiersin.org 6reported that patients with MEN1 rarely die for causes related to
hormone excess per se (126–129), while the likelihood of death
increases in the presence of pNET tumors with a malignant
behavior. Among these, gastrinomas account for more than one
half of pNET-related deaths (130). Intriguingly, causes of death
in one third of MEN1 patients do not involve MEN1-related
causes, such as cardiovascular disease and neoplasms arising
from other sites like colorectal, renal, lung, breast, and oral
cancers (126–129). It remains unclear whether these are
directly related to MEN1 and the role of menin in regulating
growth-related processes has been hypothesized to play a role (4,
131, 132). Among the cardiovascular diseases, conditions at
particular risk of complications include hyperparathyroidism
and glucose intolerance/diabetes, these latter being reported to
occur with a higher frequency in MEN1 patients (133–135).DIAGNOSIS AND MANAGEMENT
OF MEN1
Beyond work-up strategies for identification of MEN1-associated
tumors, the simultaneous presence of at least two of the three
characteristic tumors (parathyroids, pituitary, or pancreatic
islets) is considered pathognomonic for MEN1 (23). The
current clinical practice guidelines recommend three criteria
for MEN1 diagnosis (22): 1) the presence of one of the MEN1-
associated tumors in a first-degree relative of a patient with
MEN1 syndrome; 2) the identification of a germline MEN1
mutation in a subject, who could be asymptomatic and has not
yet developed radiological or biochemical signs of tumor onset;
3) the presence of two or more primary MEN1-associated
endocrine tumors (pituitary, parathyroid, or pancreatic islets).
However, genetic testing in MEN1 patients meeting the
clinical criteria could be negative (23, 89). Some studies
demonstrated that negative testing for mutations is frequent in
clinical MEN1-like presentations including a combination of
pituitary and parathyroid tumors (136, 137), while GEP NET
appeared more frequently and earlier in MEN1-positive
probands, and its development under 30 years seems to be a
predictor of a positive genetic test (24).
Biochemical screening for the MEN1 tumors onset in
asymptomatic members of families with MEN1 syndrome is
useful, since early diagnosis and treatment help reducing
morbidity and mortality from these tumors (138). Attempts to
screen for MEN1 tumors in asymptomatic relatives of affected
individuals largely rely on the measurement of calcium,
prolactin, IGF-I, and gastrointestinal hormones (22, 139).
However, the beneficial effect of routine screening and the
timing for genetic testing in pre-symptomatic individuals
remain questionable (140) and psychologically stressful (141).
Medical imaging plays a key role in detection, staging,
presurgical planning, and postsurgical surveillance (142). As
summarized in Table 3, different imaging techniques are
available to detect MEN1-associated tumors based on clinical
practice guidelines (22). Imaging is particularly important for
patients harboring a clinical diagnosis of MEN1, but showing noNovember 2020 | Volume 11 | Article 591501
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from true MEN1 (143). In this context, clinical observations
showed that mutation-negative patients often have a more
favorable clinical course (143) and may receive a less intensive
follow-up to reduce radiation exposure, healthcare costs and
anxiety (23). With regard to MEN1-PHPT, existing a genetic
underlying predisposition to multiglandular disease, parathyroid
imaging may probably result more useful to localize recurrent
and/or persistent parathyroid disease after a sub-total/total
parathyroidectomy (90).
Surgical management remains the cornerstone of MEN1
treatment, with medical therapy being used to control hormone
hypersecretion and disease symptoms depending on the tumor
extension and histotype, although the antiproliferative effect of
somatostatin analogs and everolimus have been repetitively shown
in sporadic tumors (139, 144). In the case of multiple MEN1-
associated tumors, surgical success is less frequent (22).
In MEN1-PHPT, surgery by means of subtotal or total
parathyroidectomy is the treatment of choice, the latter followed
by intramuscular reimplantation (brachioradialis muscle of the
non-dominant forearm or sternocleidomastoid muscle) ofFrontiers in Endocrinology | www.frontiersin.org 7parathyroid tissue fragments generally from the gland which
shows the smallest dimensions at the neck surgery (22, 90). The
optimal timing of surgery is debated and should be evaluated
individually. Early surgery could be difficult because glands are
minimally enlarged, which might predispose the patient to
recurrence and reoperation; at the same time, longstanding
hyperparathyroidism predisposes patient to more severe bone
disease (145). Clinical practice guidelines recommend open
bilateral neck exploration over the minimally invasive
parathyroidectomy, because all the parathyroids gland are usually
affected in MEN1 patients (22). If surgery is not possible because of
patient’s refusal, inoperability, or negative imaging, the calcimimetic
agent can be used, even if only small series showed that cinacalcet is
effective in reducing serum calcium levels in MEN1 patients (43,
146, 147).
Treatments of MEN1 associated pituitary, adrenals, thymic, and
bronchopulmonary tumors are similar to that for non-MEN1
tumors. However, it is important to remember that MEN1
thymic carcinoids, with a near-total prevalence in MEN1 smoker
males, are associated with a very high lethality and, therefore,
prophylactic thymectomy should be considered at the moment of
neck surgery for MEN1-PHPT in male patients (148).
The primary treatment for GH-, ACTH-, TSH-secreting and
symptomatic non-functioning pituitary tumors should involve
selective transsphenoidal surgical resection if clinically feasible,
with the curative intent of eradicating the tumor, or debulking the
tumor mass if compressive symptoms occur (149). Treatment
outcomes of these tumors in MEN1 syndrome are less successful
than sporadic tumors (60). In the case of 1) patient’s inoperability,
2) post-surgical tumor residual or 3) tumor relapse, 4) unfeasible
reoperation, and 5) before contemplating the use of pituitary
radiotherapy, clinicians generally employ medical or third-line
therapies depending on tumor type, clinical burden, individual
responsiveness, local therapy availabilities, and center experience.
First- or second-generation somatostatin analogs (SSAs), GH
receptor antagonist and dopamine agonists are used in case of
GH-secreting adenomas; while second-generation SSA, adrenolytic
medications, glucocorticoid receptor-antagonist, or adrenalectomy
areused for persistentCushing’s disease. In case ofTSH-omas,first-
generation SSAs, dopamine agonists, or anti-thyroid medications
can be used. Conversely, prolactinomas without neurological
involvement are primarily treated with long-acting dopamine
agonists. In the case of hypopituitarism, replacement therapy
should be initiated as per individual needs.
Treatment of adrenal tumors consists of surgery for
functioning tumors and non-functioning tumors with atypical
characteristics, tumor size >4 cm, or significant tumor growth
over a 6-months period (22, 110). In case of thymic and
bronchopulmonary carcinoids, surgery is the treatment of
choice. Where disease is advanced, additional therapies such as
radiotherapy and chemotherapy or adrenolytic drugs should be
considered (22, 110).
Surgery represents the treatment of choice also in case of
functional GEP NETs. However, treatment outcomes of these
tumors in MEN1 syndrome are less successful than sporadic
tumors for different reasons (150):TABLE 3 | Imaging techniques used to detect the main MEN1-associated
tumors.
Site Tumor Imaging
Pituitary Pituitary tumors MRI
Parathyroid
glands
Parathyroid tumors Neck US
99mTc-MIBI scintigraphy
C-11 Met-PET/CT





























Adrenal Adrenal tumors MRI or CTCT, computed tomography; EUS, endoscopic ultrasonography; FDG, fluorodeoxyglucose;
MIBI, methoxyisobutyl isonitrile; MRI, magnetic resonance imaging; PET, positron emission
tomography; pNET, pancreatic neuroendocrine tumor; SRS, somatostatin receptor
scintigraphy; ZES, Zollinger-Ellison syndrome; US, ultrasonography.November 2020 | Volume 11 | Article 591501
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the probability of surgical cure rates compared to similar sporadic
solitary tumors. In fact, only 15% of MEN1 patients are free of
disease immediately after surgery as compared to approximately
45% of non-MEN1 patients (22, 151, 152).
2) Occult metastatic disease is more frequent in MEN1 patients
with NETs than in patients with sporadic endocrine tumors.
For instance, a metastatic disease is present in up to 50% of
subjects with MEN1-related insulinomas, whereas less than
10% of sporadic insulinomas are malignant (57).
3) MEN1-associated tumors are often larger, more aggressive,
and resistant to treatment than sporadic ones. In particular,
about 85% of pituitary tumors in MEN1 patients are
macroadenomas, as opposed to 64% in non-MEN1 subjects,
they more frequently infiltrate surrounding tissues, and show
persistent hormone hypersecretion after treatment in more
than 45% of cases (60, 153).
The average life expectancy inMEN1 patients with GEP NETs is
reported to be shorter than inMEN1patientswithout (59).However,
tumor size <20 mm shows a poor tendency to grow and/or
metastasize over a long monitoring period (154), irrespective of the
underlying MEN1 genotype (155). In line with this evidence, other
studies investigated the role of surgery vs surveillance on survival and
liver metastatization in nonfunctioning pancreatic NETs (pNETs)
(156–158) after stratification by size (≤20 vs. >20 mm) as well as
proliferation indices, i.e.mitotic count andKi67 (159). These authors
demonstrated thatMEN1patientswith smallnonfunctioningpNETs
(≤20 mm) can be managed by watchful waiting, hereby avoiding
major surgery without loss of oncological safety (156–158).
With regards to medical therapy, a number of observational,
longitudinal, and randomized placebo-controlled studies have been
conducted in sporadic NETs using somatostatin analogs, peptide
receptor radionuclide therapy (PRRT), (mTOR) signaling inhibitors,
and receptor tyrosine kinase (RTK) inhibitors, all collectively
showing a statistically significant effect on disease progression
(160). Particularly PNETs are difficult to treat medically in MEN1
due to differences in growth potential, concomitant development of
other tumors, and relative insensitivity to treatment, such that
medical treatments for MEN1-related tumors have not been
properly evaluated, but rather have been employed based on
recognized effects in patients without MEN1 (161).GENOTYPE-PHENOTYPE CORRELATIONS
IN MEN1
A MEN1 gene mutation can be detrimental to gene function or
result in a protein product retaining residual functions. An
aberrant menin protein becomes impaired in its functions
through pathological interaction with transcription factors
such as Smad3, JunD, and NFkB as well as nuclear receptors,
or with proteins implicated in the apoptotic cascade such as
caspase-3, p53, or p21 (162). Lips et al. hypothesized that MEN1
germline mutations can selectively affect menin binding to its
targets and lead to distinctly aggressive clinical phenotypes (162).Frontiers in Endocrinology | www.frontiersin.org 8Moreover, it is known that a clustering of mutations is observed
in some regions of exon-2 and exon-10 which have been attributed
to the nature of the underlying repetitive nucleotides prone toDNA
polymerase errors (30, 56). Also, another observation of clustering
ofmutations at specific nucleotides in apparently unrelated families
has been attributed to founder effects (29, 163–168). However,
highlighting rare tumors among family members that are not seen
amongother individualswith the samemutationmay suggest other
mechanisms besides the mutation that can account for these
phenotypes such as epigenetics, changes in other parts of the
genome, environmental influences, immunogenicity, etc.
Specifically, it is known that dysregulation of some miRNAs
could account for parathyroid tumorigenesis (169–171), and this
could also happen in MEN1 GEP/NETs carcinogenesis (172).
Finally, epigenetic alterations could be hardly involved also in
MEN1 GEP-NET tumorigenesis (173).
Although an effort has been made to characterize the
potential genotype-phenotype correlation in MEN1, this link
remains debated to date and no definitive evidence has been
recognized (15, 25, 174). However, some authors described a
heavier or lighter clinical burden in association with some
specific mutations, and they will be subsequently described.
MEN1missense mutations have been described in association
with familiar isolated hyperparathyroidism (FIHP), an
autosomal dominant disease that potentially represents an
early stage or a milder presentation of MEN1 attributable to
an allelic variant of the MEN1 gene (175–180). Peculiarly, most
of MEN1 gene germline mutations identified in FIHP are
seemingly in-frame deletions or mild missense mutations (180).
On the other hand, studies performed in four kindreds from
Newfoundland demonstrated that a single nonsense mutation in
the MEN1 gene (R460X) was predominantly associated with
prolactinomas, carcinoids and parathyroid tumors (167, 181–
183), though the same mutation has been described in other
MEN1 cases with milder MEN1 clinical features (26, 30, 137,
164, 184–188). Therefore, there is currently no evidence of a
genotype-phenotype correlation for this mutation.
In 2011, Raef and colleagues described a MEN1 family showing
an aggressive tumor behavior associated with a monoallelic 5 kb
deletionofgenomicDNA, involving theMEN1promoterandexons
1 and 2 (189). LOHanalysis identified a somatic deletionwithin the
MEN1 locus 11q13 and the 11p15 imprinting control region (ICR)
of the maternal chromosome 11. Followingmethylation analysis of
ICR, ICR1 hypermethylation and ICR2 hypomethylation were
demonstrated in tumor specimens. These genetic alterations were
found in association with the development of multiple malignant
pNETs. Likewise, Ishida et al. described the case of aMEN1 patient
with a relapsing macroprolactinoma co-stained for FSH showing
histological features of malignancy and associated with a
metastasizing non-functioning pNET. This phenotype was
associated with menin and p27Kip1 down-regulation (190).
In 2014, Bartsch et al. retrospectively analyzed a cohort of 71
genetically confirmedMEN1patientswith the aimof evaluating the
relationship between MEN1 mutations in different interacting
domains of menin and the pNETs phenotype. The authors
demonstrated that patients with MEN1 mutations leading to lossNovember 2020 | Volume 11 | Article 591501
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higher risk of malignant pNETs with an aggressive course of the
disease and disease-related death (191). Longuini et al. analyzed a
cohort of one hundred Brazilian MEN1 germline mutant carriers,
genotyping them for the coding p27 c.326T>G (V109G) variant.
They suggest that the p27 tumor suppressor gene could represent a
disease modifier gene in MEN1 syndrome cases associated with
MEN1 germline mutations (34). Subsequently, Circelli and
colleagues confirmed, in a smaller sample of 55 Italian MEN1
patients, the possible impact of thisCDKN1B polymorphismon the
clinical course of the disease, since the MEN1-related aggressive
tumors, orothermalignancies,weremore frequent in those patients
with theCDKN1BV109Ggeneticvariant (35).However, currently it
is still not possible to clearly state whether this p27 variant behaves
as a real modifying gene or not.
In 2016, Skalniak and collegues described a three generations
family with MEN1 caused by a previously undescribed in-frame
deletion c.1231_1233delGCC (Ala411del) in theMEN1gene. Even if
the familymembers differed for their phenotypic features, all NETs
showed an aggressive behavior and a high mortality rate (192).
Lastly, a clinical survey by Palermo et al. found a strong genotype-
phenotype correlation with aggressive MEN1-related GEP NETs.
In particular, the authors described threeMEN1 patients carrying a
novel heterozygous germline mutation in exon 10 of the MEN1
gene, c.1561_1571 delACTGTCGCTGG corresponding to T521
frame-shit effect, which was associated with malignant GEP NETs
lesions and a higher rate of malignancy (193). In this regard, it is
correct to point out that patients with symptomatic MEN1
gastrinomas, a long-time treatment by H2-blockers or PPIs, may
stimulate gastric neuroendocrine cells proliferation contributing to
the clinical outcome and severity of GEP-NETs (194).
At odds with previous studies, a retrospective-prospective study
on a large Italian cohort by Marini et al. analyzedMEN1mutation
sites and features in relation to the affected menin functional
domains and clinical presentations. The authors observed a wide
variability in the age of disease onset and clinical severity even in the
presence of the same mutation, implying a lack of direct genotype-
phenotype correlations. The authors speculated that other genetic
or epigenetic factors may intervene in individual MEN1
tumorigenesis (20). Nevertheless, in this large cohort a stronger
association was documented between aggressive phenotypes and
non-sense or frameshift mutations, than with missense mutations.
It is worth to point out that the described correlations were
generally not tested in family members with the identical
genotype to determine whether all of the family members had
the aggressive phenotypes. Therefore, it is difficult to state
whether there is a genotype-phenotype correlation between
aggressive MEN1 phenotype with any type of mutation.A NOVEL MEN1 GENE MUTATION
RELATED TO AGGRESSIVE PHENOTYPE
In the context of the potential genotype-phenotype correlation, we
report on the case of a 69-year-old woman with a previously
unrecognized long history of MEN1, who was referred to ourFrontiers in Endocrinology | www.frontiersin.org 9Unit in 2017 for complicated obesity. As common practice,
patient signed an informed consent to collect clinical,
biochemical, and genetic data. The investigation was approved by
the local ethics committee, functioning according to the fourth
edition of the Guidelines on the Practice of Ethics Committees in
Medical Research With Human Participants. Unfortunately,
because of the suffering for her long clinical history, not
adequately managed from the beginning, and for the diagnosis
that cameonly on the occasion of her hospitalization at our hospital
unit, understandably exhausted, she did not give consent to carry
out molecular studies on any of her surgically removed tissues. Her
MEN1-related clinical record was noticeable for 1) a pituitary
macroprolactinoma cured after trans-sphenoidal adenomectomy
andexternal conventional radiotherapy in1980, 2)PHPTsurgically
treated by excision of a single upper left parathyroid adenoma in
1981 at the age of 35 years, 3) two duodenal gastrinomas diagnosed
in 2005 and left untreated according to the patient’s choice. While
the diagnosis of pituitary and parathyroid disease was nearly
synchronous, her osteoporotic bone involvement was severe due
to dual dorsal vertebral fractures causing an early exaggerated
thoracic kyphosis and compromising her biomechanical
performance. Reportedly, no genetic analysis had been performed
on the patient or her relatives at that stage. Upon admission to our
unit, the clinical and imaging work-up showed: a normal
(unstimulated) pituitary function; hypercalcemia with 3.5×
elevation of PTH levels due to an apparently single left
parathyroid adenoma identified at ultrasound and MIBG-
scintigraphy; hypergastrinemia and high chromogranin A levels
associated with endoscopic, scintigraphic (octroscan) and MRI
evidence of three separate lesions located in the anterior gastric
wall, in the duodenal loop, and in the pancreas head. A CT scan
excluded systemic metastases. Because of associated ZES, she
started proton pump-inhibitors. For her osteoporosis, she started
antiresorptive treatment with oral alendronate as she refused i.v.
administrationwithamino-bisphosphonates available by this route.
After surgical and anesthesiological consultation, she underwent
total parathyroidectomy and auto-transplantation of three
parathyroid fragments within the brachioradialis muscle.
Abdominal surgery was contraindicated for her poor clinical
conditions, and she was started on octreotide LAR (30 mg/28d),
leading to clinical control and near-normalization of gastrin and
CgA levels. Shewas subsequently followedup at 3months intervals.
Due to new onset metrorrhagia, the patient was re-admitted to our
unit in 2018 to undergo a diagnostic workup. Transvaginal
ultrasound and pelvic MRI showed endometrial thickening, and
hysteroscopic endomyometrial biopsy revealed a high-grade
neuroendocrine endometrial carcinoma (G3) staining negative
for gastrin and showing immunopositivity for p16, p53, CKpan,
chromogranin A, vimentin, estrogen, and progesterone. Ki-67 was
50%. The patient’s conditions contraindicated gynecological
surgery, and she refused palliative antineoplastic treatment.
Genetic analysis by sequencing of the coding sequence of the
MEN1 gene (NM_130799.2) and CDKN1B (NM_004064.3)
resulted in the identification of the missense variant c.836C>A in
exon6 resulting in the amino acid changep.A279D inheterozygous
state. This variant was not found in genomic variation databasesNovember 2020 | Volume 11 | Article 591501
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and represented a non-conservative change leading to the switch
from a hydrophobic to a basic amino acid (BLOSUM62=-2;
Grantham Distance =126), located in a very conserved position in
the protein domain involved in the interaction of menin protein
with FANCD2. Previous in silico prediction tools of variation
effects, such as SIFT, Mutation Tester, Poly Phen, Provean, and
A-GVGD, suggested a probable pathogenic effect of this
substitution on the aberrant patient’s phenotype. Deletions in
MEN1 gene were excluded through MLPA analysis (MRC
Holland, P017-D1 probemix). Potential overlap with other
published gene mutations sharing the same amino acid sequence
or functional domain effects was also excluded. We subsequently
evaluated the co-segregation of the afore-mentionedMEN1 variant
in the proband family (Figure 1). A total of 16 relatives, including
her old parents, were screened but none was found to carry the
index mutation or any other variant, likewise none was presenting
clinical manifestations suggestive of MEN1. Further, the possible
contribution to the proband phenotype of BRCA1/2mutations was
excluded through NGS (Illumina, NY, USA) and MLPA analysis
(MRCHolland, P002-D1BRCA1andP090-B1BRCA2probemix).DISCUSSION
Clinical guidelines focus on early detection of MEN1-related
tumors, namely parathyroid adenomas, GEP NETs, and pituitary
adenomas (22, 139, 144). An aggressive or aberrant behavior of
endocrine tumors has been occasionally described in patients
with MEN1 syndrome, raising the following questions: do some
MEN1 patients with specific mutations carry an increased risk of
aberrant clinical progression requiring in-depth diagnostic and
therapeutic assessment? Also, are tumor-related manifestations
or the disease course dependent on the type of mutation? Earlier
studies failed to show strong genotype-phenotype associations,
while more novel studies seem to dispute this viewpoint. It isFrontiers in Endocrinology | www.frontiersin.org 10suggestive to speculate that the type of MEN1 gene mutation
could influence the clinical manifestations of MEN1. In MEN1
syndrome exhibiting a non-aggressive phenotype, frameshift or
nonsense leading to a truncated and consequently inactivated
protein have been identified in most cases (120). Likewise, FIHP
is characterized by the onset of primary hyperparathyroidism
alone and is related to specific mutations of MEN1 gene that
often include missense mutations and only occasionally
nonsense or frameshift mutations (22, 89). Conversely, some
specific mutations seem to be associated with a less favorable
prognosis. For example, subjects with MEN1 mutations leading
to a loss of interaction with the checkpoint kinase 1-interacting
domain have a higher risk of malignant pNETs with aggressive
phenotype and higher prevalence of disease-related death (192).
Peculiarly, patients with mutations that affect the JunD-
interacting domain have a higher risk of death for a typical
MEN1 tumor, requiring a more aggressive therapeutic approach
(195). In keeping with these indications, the novel missense
variant herein reported c.836C>A resulting in the amino acid
change p.A279D in heterozygous state, leads to a change from
alanine to aspartic acid with potential aggressive behavior. At
odds with studies minimizing the clinical impact of missense
mutations compared to frameshift or non-sense mutations (20,
24), the missense variant described in our index case stands out
for its aberrant and aggressive clinical manifestations developing
long after the first clinical manifestation of MEN1.CONCLUSIONS
Current clinical practice guidelines for MEN1 recommend a
screening program for MEN1 patients and their families with the
aim of reducing morbidity and mortality and achieving an early
detection of MEN1-related tumors (22, 139). Although
genotype-phenotype correlations are difficult to demonstrate,
our index case and other reports suggest that patients withFIGURE 1 | Pedigree. The black arrow indicates the affected patient. NN, homozygote without mutation; MN, heterozygous with mutation; nd, not screened.November 2020 | Volume 11 | Article 591501
Mele et al. Genotype-Phenotype Correlations in MEN1suggestive genotype-phenotype correlations should undergo a
closer follow-up and surveillance with an interdisciplinary
approach. In fact, our team was involved and intervened only
at a relatively advanced stage in the clinical history of this case,
when the patient was understandably exhausted and did not give
consent to carry out molecular studies on her surgically removed
tissues. Consequently, we lack molecular data on menin
expression and function, LOH studies at the tumor tissue level,
as also on possible involvement of specific miRNAs. This aspect
further confirms the importance that subjects affected by rare
and complex pathologies such this are taken in charge from theFrontiers in Endocrinology | www.frontiersin.org 11beginning by expert multidisciplinary teams, also capable of
managing the psychological aspects and implications linked to
genetic and repeatedly clinical management complexity.AUTHOR CONTRIBUTIONS
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77. Juodelė L, Serapinas D, Sabaliauskas G, Krasauskienė A, Krasauskas V,
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